(Q35848351)

English

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

scientific article published on 7 July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andrew Raubitschek

27

object named as

Andrew Raubitschek

0 references

author name string

Auayporn Nademanee

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Stephen Forman

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Arturo Molina

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Henry Fung

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

David Smith

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Andy Dagis

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Cheuk Kwok

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Dave Yamauchi

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Anne-Line Anderson

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Peter Falk

10

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Amrita Krishnan

11

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mark Kirschbaum

12

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Neil Kogut

13

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ryotaro Nakamura

14

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Margaret O'donnell

15

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Pablo Parker

16

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Leslie Popplewell

17

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Vinod Pullarkat

18

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Roberto Rodriguez

19

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Firoozeh Sahebi

20

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Eileen Smith

21

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

David Snyder

22

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Anthony Stein

23

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ricardo Spielberger

24

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jasmine Zain

25

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Christine White

26

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Andrew Raubitschek

27

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

7 July 2005

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

106

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

2896-2902

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Radiolabeled antibody therapy of B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

11 July 2018

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895300

24 September 2018

Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous hematopoietic stem cell transplantation for mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16002426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2005-03-1310

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35848351&oldid=1749486166"